Similar articles for PMID: 36521042

Year	Number of Results
1994	1
1996	3
1997	1
1998	1
1999	2
2000	1
2001	4
2002	1
2004	3
2005	5
2006	3
2008	3
2009	2
2010	4
2011	4
2012	5
2013	3
2014	6
2015	2
2016	14
2017	9
2018	14
2019	8
2020	6
2021	7
2022	6
2024	0

1

Analysis of Clinical and Biochemical Characteristics of Patients With Genetically Confirmed Familial Hypercholesterolemia in Russian North Western District Residents.

Korneva VA, Zacharova FM, Mandelstam MY, Bogoslovskaya TY, Orlov AV, Vasilyev VB, Kuznetsova TY. Korneva VA, et al. Kardiologiia. 2022 Nov 30;62(11):33-39. doi: 10.18087/cardio.2022.11.n2232. Kardiologiia. 2022. PMID: 36521042 English, Russian.

2

Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.

Pek SLT, Dissanayake S, Fong JCW, Lin MX, Chan EZL, Tang JI, Lee CW, Ong HY, Sum CF, Lim SC, Tavintharan S. Pek SLT, et al. Atherosclerosis. 2018 Feb;269:106-116. doi: 10.1016/j.atherosclerosis.2017.12.028. Epub 2017 Dec 27. Atherosclerosis. 2018. PMID: 29353225

3

Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.

Santos PC, Morgan AC, Jannes CE, Turolla L, Krieger JE, Santos RD, Pereira AC. Santos PC, et al. Atherosclerosis. 2014 Mar;233(1):206-10. doi: 10.1016/j.atherosclerosis.2013.12.028. Epub 2014 Jan 4. Atherosclerosis. 2014. PMID: 24529145

4

Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.

Rubba P, Gentile M, Marotta G, Iannuzzi A, Sodano M, De Simone B, Jossa F, Iannuzzo G, Giacobbe C, Di Taranto MD, Fortunato G. Rubba P, et al. Eur J Prev Cardiol. 2017 Jul;24(10):1051-1059. doi: 10.1177/2047487317702040. Epub 2017 Mar 29. Eur J Prev Cardiol. 2017. PMID: 28353356

5

Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations.

Rabacchi C, Bigazzi F, Puntoni M, Sbrana F, Sampietro T, Tarugi P, Bertolini S, Calandra S. Rabacchi C, et al. J Clin Lipidol. 2016 Jul-Aug;10(4):944-952.e1. doi: 10.1016/j.jacl.2016.04.005. Epub 2016 Apr 21. J Clin Lipidol. 2016. PMID: 27578127

6

Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing.

Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, Hawe E, Iversen A, Wray R, Crook MA, Wierzbicki AS. Humphries SE, et al. J Mol Med (Berl). 2006 Mar;84(3):203-14. doi: 10.1007/s00109-005-0019-z. Epub 2005 Dec 31. J Mol Med (Berl). 2006. PMID: 16389549

7

Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.

Grenkowitz T, Kassner U, Wühle-Demuth M, Salewsky B, Rosada A, Zemojtel T, Hopfenmüller W, Isermann B, Borucki K, Heigl F, Laufs U, Wagner S, Kleber ME, Binner P, März W, Steinhagen-Thiessen E, Demuth I. Grenkowitz T, et al. Atherosclerosis. 2016 Oct;253:88-93. doi: 10.1016/j.atherosclerosis.2016.08.037. Epub 2016 Aug 26. Atherosclerosis. 2016. PMID: 27596133

8

[Identification of a novel mutation at the point of low density lipoprotein receptor gene from a subject with familial hypercholesterolemia].

Liu YR, Tao QM, Chen JZ, Tao M, Guo XG, Shang YP, Zhu JH, Zhang FR, Zheng LR, Wang XX. Liu YR, et al. Sheng Li Xue Bao. 2004 Oct 25;56(5):566-72. Sheng Li Xue Bao. 2004. PMID: 15497035 Free article. Chinese.

9

Molecular genetics of familial hypercholesterolemia in Israel-revisited.

Durst R, Ibe UK, Shpitzen S, Schurr D, Eliav O, Futema M, Whittall R, Szalat A, Meiner V, Knobler H, Gavish D, Henkin Y, Ellis A, Rubinstein A, Harats D, Bitzur R, Hershkovitz B, Humphries SE, Leitersdorf E. Durst R, et al. Atherosclerosis. 2017 Feb;257:55-63. doi: 10.1016/j.atherosclerosis.2016.12.021. Epub 2016 Dec 18. Atherosclerosis. 2017. PMID: 28104544 Free article.

10

Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.

Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Inoue T, Mori M, Tada H, Nakanishi C, Yagi K, Yamagishi M, Ueda K, Takegoshi T, Miyamoto S, Inazu A, Koizumi J; Hokuriku FH Study Group. Mabuchi H, et al. Atherosclerosis. 2014 Sep;236(1):54-61. doi: 10.1016/j.atherosclerosis.2014.06.005. Epub 2014 Jun 26. Atherosclerosis. 2014. PMID: 25014035

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year